Tonix Pharmaceuticals Holding Corp

Tonix Pharma Surges as CNS Disorder Pipeline Gains Investor Confidence

Tonix Pharmaceuticals is advancing CNS‑disorder therapies for fibromyalgia and PTSD, showing market resilience and investor confidence amid biotech volatility.

Tonix Pharmaceuticals Holding Corp
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

07/11/2025, 07:35

2 minutes to read

Tonix Pharmaceuticals Surpasses EPS Expectations in Q1 2025 Amid Revenue Shortfall

Tonix Pharmaceuticals reported Q1 2025 financial results, with a GAAP EPS of -$2.84 and revenue of $2.43 million, despite surpassing earnings expectations.

Tonix Pharmaceuticals Holding Corp
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

13/05/2025, 06:36

2 minutes to read

Newer articles